Lincoln Pharmaceuticals Limited (BSE: 531633, NSE: LINCOLN), one of India’s leading healthcare companies has reported a consolidated net profit of Rs. 20.01 crore for the Q2 FY 2025-26 as compared to the net profit of Rs. 26.35 crore reported in Q2 FY 2024-25. Total income for the quarter ended September 2025 was reported at Rs. 170.60 crore as compared to the total income of Rs. 171.19 crore in Q2 FY2024-25. EBITDA for Q2 FY26 was reported at Rs. 32.66 crore as compared to EBITDA of Rs. 38.35 crore in Q2 FY25. Shareholders at the 31st Annual General Meeting (AGM) approved a dividend of Rs. 1.80 per share (18%) for the FY 2024-25.

Company is targeting a revenue of Rs. 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments. Company is committed to expanding its global footprint while meeting diverse healthcare needs. Foreign Institutional Investors (FIIs) have steadily raised their holding in the company to 4.73% as on 30th September 2025.

Highlights: - H1FY26 Results

For the six months ended September 2025 (H1FY26), The company has reported standalone net profit of Rs. 47.71 crore as compared to the net profit of Rs. 50.03 crore in H1 FY25. Total Income for the H1 FY26 was reported at Rs. 339.93 crore as compared to H1 FY25 total income of Rs. 328.88 crore. EBITDA for the H1 FY26 ended September 2025 was reported at Rs. 71.74 crore as compared to Rs. 71.50 crore EBITDA in H1 FY25. EPS for H1 FY26 was reported at Rs. 23.79 per share. 

Speaking on the financial performance and future plans, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “We are pleased to report another strong quarter, reflecting our continued focus on sustainable growth and value creation. With consistent performance across all business verticals, we remain committed to achieving our strategic goal of reaching Rs. 1,000 crore in revenue within the next three years. Our growth momentum is supported by expansion into high-value therapeutic segments such as cardiac, diabetic, dermatology, and ENT, along with new product introductions and entry into emerging markets. The commissioning of our Bulk Drug Manufacturing Plant and progress at our Cephalosporin facility further strengthen our backward integration and export capabilities. Supported by our robust R&D, operational excellence, and a strong product pipeline, we are confident of maintaining 15–18% annual growth. With a debt-free balance sheet, we are well positioned to deliver sustainable, profitable growth and enhance long-term shareholder value.”

The company’s growth strategy focuses on expanding its global footprint by registering new products for export, enhancing domestic market presence, and utilizing state-of-the-art manufacturing facilities that meet international standards. With a strong foundation in the acute segment, the company is now building a robust portfolio in lifestyle and chronic segments, particularly in women’s healthcare and dermatology. Supported by healthy cash accruals, no-term debt, and strong return ratios, the company’s liquidity remains solid.

Company remains focused on strengthening its presence in regulated and semi-regulated markets. It currently exports to 60+ countries across East and West Africa, Central and North America, Latin America, and Southeast Asia. Company aims to expand this footprint to 90 countries over next 2–3 years. With recent entry into the Canadian market and approvals from TGA - Australia and EU GMP, the company is poised for further global expansion.

Also Read: Justpay Reports Record Profitability with 61% YoY Revenue Growth

Company has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents. Company showcases its dedication to innovation and growth through a robust portfolio boasting over 1,700 registered products, with 700 more in development.